CD79a Antibody

Flow cytometry: 1-2ug/million cells in 0.1ml,Immunofluorescence: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml

Optimal dilution of the antibody should be determined by the researcher.

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

Purified

0.2 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

IgM complex isolated from Daudi cells was used as the immunogen for this CD79a antibody.

This CD79a antibody is available for research use only.

Cell surface, cytoplasmic

Protein G affinity chromatography

Human

P11912